These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23634822)

  • 1. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
    Román VR; Jensen KJ; Jensen SS; Leo-Hansen C; Jespersen S; da Silva Té D; Rodrigues CM; Janitzek CM; Vinner L; Katzenstein TL; Andersen P; Kromann I; Andreasen LV; Karlsson I; Fomsgaard A
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1504-12. PubMed ID: 23634822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection.
    Karlsson I; Brandt L; Vinner L; Kromann I; Andreasen LV; Andersen P; Gerstoft J; Kronborg G; Fomsgaard A
    Clin Immunol; 2013 Feb; 146(2):120-30. PubMed ID: 23314272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes.
    Kloverpris H; Karlsson I; Bonde J; Thorn M; Vinner L; Pedersen AE; Hentze JL; Andresen BS; Svane IM; Gerstoft J; Kronborg G; Fomsgaard A
    AIDS; 2009 Jul; 23(11):1329-40. PubMed ID: 19528789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of conserved subdominant HIV Type 1 CD8(+) T Cell epitopes restricted within common HLA Supertypes for therapeutic HIV Type 1 vaccines.
    Karlsson I; Kløverpris H; Jensen KJ; Stryhn A; Buus S; Karlsson A; Vinner L; Goulder P; Fomsgaard A
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1434-43. PubMed ID: 22747336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.
    Vinner L; Holmgren B; Jensen KJ; Esbjornsson J; Borggren M; Hentze JL; Karlsson I; Andresen BS; Gram GJ; Kloverpris H; Aaby P; Da Silva ZJ; Fenyö EM; Fomsgaard A
    APMIS; 2011 Aug; 119(8):487-97. PubMed ID: 21749448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
    Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic HIV Peptide Vaccine.
    Fomsgaard A
    Methods Mol Biol; 2015; 1348():351-7. PubMed ID: 26424286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
    Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
    J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
    Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
    Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct.
    Cardinaud S; Bouziat R; Rohrlich PS; Tourdot S; Weiss L; Langlade-Demoyen P; Burgevin A; Fiorentino S; van Endert P; Lemonnier FA
    AIDS; 2009 Sep; 23(15):1945-54. PubMed ID: 19644347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients.
    Fonseca SG; Coutinho-Silva A; Fonseca LA; Segurado AC; Moraes SL; Rodrigues H; Hammer J; Kallás EG; Sidney J; Sette A; Kalil J; Cunha-Neto E
    AIDS; 2006 Nov; 20(18):2263-73. PubMed ID: 17117012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.
    Palma P; Romiti ML; Li Pira G; Montesano C; Mora N; Aquilani A; Santilli V; Tchidjou HK; Ivaldi F; Giovannelli L; Pontrelli G; Borra G; Blomberg P; Gudmundsdotter L; Bråve A; Montano M; Bernardi S; Manca F; Wahren B; Rossi P
    Vaccine; 2011 Sep; 29(39):6810-6. PubMed ID: 21216310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
    J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.
    Horton H; Havenar-Daughton C; Lee D; Moore E; Cao J; McNevin J; Andrus T; Zhu H; Rubin A; Zhu T; Celum C; McElrath MJ
    J Virol; 2006 Oct; 80(19):9779-88. PubMed ID: 16973582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.